Acrivon Therapeutics, Inc.

NasdaqGM:ACRV Stock Report

Market Cap: US$180.0m

Acrivon Therapeutics Management

Management criteria checks 3/4

Acrivon Therapeutics' CEO is Peter Blume-Jensen, appointed in Mar 2018, has a tenure of 6.83 years. total yearly compensation is $6.47M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 5.95% of the company’s shares, worth $10.71M. The average tenure of the management team and the board of directors is 2.8 years and 3.1 years respectively.

Key information

Peter Blume-Jensen

Chief executive officer

US$6.5m

Total compensation

CEO salary percentage9.7%
CEO tenure6.8yrs
CEO ownership5.9%
Management average tenure2.8yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Dec 12

We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

Nov 17
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 18

Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?

Jul 17
Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation

Mar 29
Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Oct 05
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Jun 22
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Feb 22
We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Peter Blume-Jensen's remuneration changed compared to Acrivon Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$77m

Jun 30 2024n/an/a

-US$69m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$6mUS$629k

-US$60m

Sep 30 2023n/an/a

-US$50m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$22mUS$536k

-US$31m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$757kUS$430k

-US$16m

Compensation vs Market: Peter's total compensation ($USD6.47M) is above average for companies of similar size in the US market ($USD1.42M).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.

CEO

Peter Blume-Jensen (61 yo)

6.8yrs

Tenure

US$6,465,973

Compensation

Mr. Peter Blume-Jensen, MD, PhD., serves as a Member of Advisory Board at Kernal Biologics, Inc. Mr. Blume-Jensen is the Founder, Chairman, President, Chief Executive Officer and Acting Chief Scientific Of...

Leadership Team

NamePositionTenureCompensationOwnership
Peter Blume-Jensen
Co-Founder6.8yrsUS$6.47m5.95%
$ 10.7m
Kristina Masson
Co-Founderno dataUS$739.78k0.97%
$ 1.7m
Mary-Alice Miller
Chief Legal Officer2.3yrsUS$697.00k0.048%
$ 85.7k
Rasmus Holm-Jorgensen
Chief Financial Officer2.8yrsUS$2.30m0.053%
$ 95.4k
Eric Devroe
Chief Operating Officer2.4yrsUS$2.18m0.16%
$ 295.8k
Katharine Peterson
Vice President of Finance & Accountingno datano data0.015%
$ 26.2k
Adam Levy
Senior VP and Head of Investor Relations & Corporate Affairs1.5yrsno datano data
Bruce Close
Vice President of Quality & Compliance2.8yrsno datano data
Parvin Miah
VP & Head of Human Resources2yrsno datano data
Erick Gamelin
Chief Development Officer3.8yrsUS$538.08k0.022%
$ 40.2k
Jesper Olsen
Academic Co-Founderno datano datano data
Joon Jung
VP & Head of Data Science2.8yrsno datano data

2.8yrs

Average Tenure

51yo

Average Age

Experienced Management: ACRV's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Blume-Jensen
Co-Founder6.8yrsUS$6.47m5.95%
$ 10.7m
Kristina Masson
Co-Founder6.8yrsUS$739.78k0.97%
$ 1.7m
Jesper Olsen
Academic Co-Founder3.1yrsno datano data
George Demetri
Member of Scientific Advisory Board3.1yrsno datano data
Ivana Magovcevic-Liebisch
Independent Directorless than a yearno data0.012%
$ 20.9k
Sharon Shacham
Independent Director4.3yrsUS$58.13k0.063%
$ 113.1k
Michael Tomsicek
Independent Director2.3yrsUS$68.13k0.063%
$ 113.1k
Charles Baum
Independent Director1.6yrsUS$325.07k0.032%
$ 57.4k
Robert Abraham
Member of Scientific Advisory Board3.1yrsno datano data
Santhosh Palani
Independent Directorless than a yearno data0.0087%
$ 15.7k
Derek DiRocco
Independent Director3.2yrsUS$65.00k0.063%
$ 113.1k
Timothy A. Yap
Member of Scientific Advisory Board3.1yrsno datano data

3.1yrs

Average Tenure

57yo

Average Age

Experienced Board: ACRV's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 10:49
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acrivon Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Etzer DaroutBMO Capital Markets Equity Research
Emily BodnarH.C. Wainwright & Co.